Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders
- 1 September 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 35 (4)
Abstract
Objectives: Although pharmacogenetic tests provide the information on a genotype and the predicted phenotype, these tests do not themselves provide the interpretation of data for a physician. Currently, there are approximately two dozen pharmacogenomic clinical decision support systems (CDSSs) used in psychiatry. Implementation of the CDSSs forming the recommendations on drug and dose selection according to the results of pharmacogenetic testing is an urgent task. Fulfillment of this task will allow increasing the efficacy of therapy and decreasing the risk of undesirable side effects. Methods: The study included 118 male patients (48 in the main group and 70 in the control group) with affective disorders and comorbid alcohol use disorder. To evaluate the efficacy and safety of therapy, several international psychometric scales and rating scales to measure side effects were used. Genotyping was performed using the real-time polymerase chain reaction with allele-specific hybridization. Pharmacogenetic testing results were interpreted using free software PGX2 (LLE Medicine, Russian Federation, Biomedical Cluster of Skolkovo, Moscow Innovative Cluster; www.pgx2.com). Results: The statistically significant differences across the scores on psychometric scales were revealed. For instance, the total score on the Hamilton Rating Scale for Depression by day 9 was 9.0 [8.0; 10.0] for the main group and 11.0 [10.0; 12.0] (p<0.001) for the control group and by day 16 it was 4.0 [2.0; 6.0] for the main group and 14.0 [13.0; 14.0] (p<0.001) for the control group. The UKU Side-Effect Rating Scale (UKU) also revealed a statistically significant difference. The total score on the UKU scale by day 9 was 4.0 [4.0; 5.0] for the main group and 5.0 [5.0; 6.0] (p<0.001) for the control group and by day 16 this difference grew significantly: 3.0 [0.0; 4.2] for the main group and 9.0 [7.0; 11.0] (p<0.001) for the control group. Conclusions: Pharmacogenetic-guided personalization of the drug dose in patients with affective disorders and comorbid alcohol use disorder can reduce the risk of undesirable side effects and pharmacoresistance. It allows recommending the use of pharmacogenetic CDSSs for optimizing drug dosage.Keywords
Funding Information
- Russian Federation (МК-2460.2018.7)
- the Russian Science Foundation (18-75-10073)
This publication has 43 references indexed in Scilit:
- The DSM‐5: Classification and criteria changesWorld Psychiatry, 2013
- Using a pharmacogenomic algorithm to guide the treatment of depressionTranslational Psychiatry, 2012
- Suffering in Silence: Reasons for Not Disclosing Depression in Primary CareThe Annals of Family Medicine, 2011
- Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depressionInternational Clinical Psychopharmacology, 2010
- The Effect of Alcohol Treatment on Social Costs of Alcohol DependenceMedical Care, 2010
- Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17Drug Metabolism and Disposition, 2007
- Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant ActionArchives of General Psychiatry, 2006
- Efficacy of antidepressants in adultsBMJ, 2005
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987